Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial
Kayvon Modjarrad(Pfizer (United States)), Emmanuel Feroldi(Sanofi (France)), Jack Hutter, Manuel Vangelisti(Sanofi (France)), Sheila A. Peel(Henry M. Jackson Foundation), Mihret F. Amare(Henry M. Jackson Foundation), Badryah Omar(Henry M. Jackson Foundation), Nathalie Mantel(Sanofi (France)), Valentine Delore(Sanofi (France)), Melinda Hamer, Melissa E. Greenleaf(Walter Reed Army Institute of Research), Janice M. Darden(Henry M. Jackson Foundation), Paul T. Scott(Walter Reed Army Institute of Research), Haritha Adhikarla(Yale University), Erica L Sondergaard(Walter Reed Army Institute of Research), Ajay Parikh(Henry M. Jackson Foundation), Michael Koren(Walter Reed Army Institute of Research), Christine E Lee(U.S. President's Malaria Initiative), Yukun Wu(Sanofi (United States)), Brittany Ober-Shepherd(Henry M. Jackson Foundation), Kamila S Kourbanova(Walter Reed Army Institute of Research), Ada-Marie Minutello(Sanofi (France)), Melanie McCauley(Henry M. Jackson Foundation), Merlin L Robb(Henry M. Jackson Foundation), Melissa E Martinez(Walter Reed Army Institute of Research), Ivelese Guzman(Walter Reed Army Institute of Research), Andrey Rojas P(Asociación Colombiana de Facultades de Ingeniería), Meshell Morrison(Walter Reed Army Institute of Research)
Cited by 8
Related Papers
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
|SpringerPlus|2015|206